As of March, 27 Aeterna Zentaris Inc. (AEZS) EPS Estimated At $-0.19

Aeterna Zentaris Inc. (NASDAQ:AEZS)’s quarterly earnings will be announced on March, 27., as reported by Faxor. The EPS diference is $0.05 or 20.83 % up from last years number. Previous year: $-0.24; Analysts forcast: $-0.19. Analysts at Wall Street see Aeterna Zentaris Inc.’s 26.67 % negative EPS growth compared to $-0.15 EPS for previous quarter. AEZS is hitting $3.98 during the last trading session, after decreased 0.50%.Currently Aeterna Zentaris Inc. is uptrending after 122.35% change in last March 15, 2018. AEZS has also 147,173 shares volume. AEZS outperformed by 117.98% the S&P500.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health.The company has $65.03 million market cap. The company's product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency.7.45 is the P/E ratio. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology.

For more Aeterna Zentaris Inc. (NASDAQ:AEZS) news published briefly go to:,,, or The titles are as follows: “Aeterna Zentaris’ (AEZS) CEO Michael V. Ward on Q1 2018 Results – Earnings Call Transcript – Seeking Alpha” published on May 08, 2018, “5 Tiny Biotech Stocks With Superb Growth Potential – Nasdaq” on February 13, 2019, “Strongbridge completes $181.7M sale of hormone drug to Novo Nordisk – Philadelphia Business Journal” with a publish date: December 19, 2018, “Aeterna Zentaris Reports First Quarter 2018 Financial and Operating Results – GlobeNewswire” and the last “AEZS: The Unique Selling Points Of Macrilen – Seeking Alpha” with publication date: December 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.